安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Dyslipidemia: Causes, symptoms, and treatment - Medical News Today
It can be caused by genetic conditions or lifestyle factors, such as consuming too many foods high in saturated fats Learn more about symptoms and how dyslipidemia is treated
- Dyslipidemia - Wikipedia
Dyslipidemia is a metabolic disorder characterized by abnormally high or low amounts of any or all lipids (e g fats, triglycerides, cholesterol, phospholipids) or lipoproteins in the blood [1]
- ACC AHA Issue Updated Guideline for Managing Lipids, Cholesterol
The American College of Cardiology (ACC), the American Heart Association and nine other leading medical associations, today issued an updated guideline for the management of dyslipidemia—abnormal levels of one or more types of lipids or lipoproteins in the blood, including cholesterol and triglycerides It is estimated 1 in 4 U S adults has high levels of low-density lipoprotein-cholesterol
- Dyslipidemia - Hormonal and Metabolic Disorders - Merck Manual Consumer . . .
Dyslipidemia is a high level of cholesterol and or triglycerides or a low level of high-density lipoprotein (HDL) cholesterol Lifestyle, genetics, disorders (such as low thyroid hormone levels or kidney disease), medications, or a combination can contribute
- 2026 ACC AHA Multisociety Dyslipidemia Guideline Released
The 2026 ACC AHA Multisociety Dyslipidemia Guideline strongly supports dyslipidemia measurement and management through the lifetime, promoting universal lipid testing and management of dyslipidemia through healthy nutrition, lifestyle, and medication for individuals with and without clinical atherosclerotic cardiovascular disease (ASCVD)
- What Is Dyslipidemia? Causes, Symptoms, and Treatment
Dyslipidemia means your blood fats are out of balance Learn what causes it, how it harms your arteries, and how diet, lifestyle, and medication can help
- 2026 Guideline on the Management of Dyslipidemia
This guideline retires and replaces the 2018 AHA ACC Guideline on the Management of Blood Cholesterol and is retitled the 2026 Guideline on the Management of Dyslipidemia to reflect the evolving understanding of atherosclerotic cardiovascular disease (ASCVD) risk associated with atherogenic lipoproteins beyond low-density lipoprotein cholesterol (LDL-C), including triglyceride-rich remnant
- 2026 ACC AHA AACVPR ABC ACPM ADA AGS APhA ASPC NLA PCNA . . . - PubMed
The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a)
|
|
|